ViroLogik is a biopharmaceutical company which is developing innovative drugs for treatment of viral diseases. The focus is on Hepatitis C (HCV). Other indications are HIV- (Human Immunodeficiency Virus, AIDS) and IAV- (Influenza-A Virus) infections. ViroLogik is following a novel strategy to prevent formation of drug resistance.

ViroLogik has clinical proof of principle with a proteasome inhibitor in Hepatitis C patients refractory to standard therapy. Formal preclinical development of ViroLogik’s own development candidate VL01 is progressing. A First-in-Man clinical Phase Ia study with VL01 is scheduled to start early in 2011.

ViroLogik is following a novel strategy to prevent formation of drug resistance. The approach aims at inhibition of the highly conserved host cell proteasome which is essential for viral replication. This is in contrast to many current drugs which target fast mutating viral proteins and, hence, are prone to induction of drug resistance.

ViroLogik is led by a seasoned management team and currently is financed by venture capital investors. To date about € 18.2 million were raised in total. The company was established in Erlangen near Nuremberg, Germany in 2006.